L R Hoes
Overview
Explore the profile of L R Hoes including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
177
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Verkerk K, Zeverijn L, van de Haar J, Roepman P, Geurts B, Spiekman A, et al.
ESMO Open
. 2025 Jan;
10(1):104112.
PMID: 39778224
Background: Many patients with cancer exhibit primary or rapid secondary resistance to targeted therapy (TT). We hypothesized that a higher number of altered oncogenic signaling pathways [pathway alteration load (PAL)]...
2.
van Berge Henegouwen J, Jebbink M, Hoes L, van der Wijngaart H, Zeverijn L, van der Velden D, et al.
Eur J Cancer
. 2022 Jun;
171:114-123.
PMID: 35716537
Introduction: In 1-3% of non-small cell lung cancer (NSCLC) human epidermal growth factor 2 (HER2) mutations are identified as a genomic driver. Nevertheless, no HER2-targeted treatment is approved for NSCLC....
3.
van Berge Henegouwen J, van der Wijngaart H, Zeverijn L, Hoes L, Meertens M, Huitema A, et al.
Cancer Chemother Pharmacol
. 2022 May;
90(1):97-104.
PMID: 35598186
Introduction: The combination of vemurafenib, a proto-oncogene B-Raf inhibitor (BRAFi) and cobimetinib, an inhibitor of mitogen-activated protein kinase kinase (MEKi) has shown to improve survival in patients with BRAF V600-mutated...
4.
Ooft S, Weeber F, Schipper L, Dijkstra K, McLean C, Kaing S, et al.
ESMO Open
. 2021 Apr;
6(3):100103.
PMID: 33887686
Background: Organoid technology has recently emerged as a powerful tool to assess drug sensitivity of individual patient tumors in vitro. Organoids may therefore represent a new avenue for precision medicine,...
5.
van der Velden D, Hoes L, van der Wijngaart H, van Berge Henegouwen J, van Werkhoven E, Roepman P, et al.
Nature
. 2019 Oct;
574(7776):127-131.
PMID: 31570881
The large-scale genetic profiling of tumours can identify potentially actionable molecular variants for which approved anticancer drugs are available. However, when patients with such variants are treated with drugs outside...
6.
van Waalwijk van Doorn-Khosrovani S, Pisters-van Roy A, van Saase L, van der Graaff M, Gijzen J, Sleijfer S, et al.
Ann Oncol
. 2019 May;
30(5):663-665.
PMID: 31038154
No abstract available.